Prof Shalini Vinod
banner
shalinivinod.bsky.social
Prof Shalini Vinod
@shalinivinod.bsky.social
Radiation Oncologist / #Lung Cancer / #Quality / #Equity
Important to assess quality of decision making at MDMs. Is the patient voice being heard? Do nurses contribute? www.sciencedirect.com/science/arti...
Quality of Decision-making at Oncology Multidisciplinary Team Meetings: A Structured Observational Study
Multidisciplinary meetings (MDMs) are crucial in cancer care, with increasing attention on improving the quality of decision-making. Validated tools h…
www.sciencedirect.com
October 10, 2025 at 7:32 PM
Reposted by Prof Shalini Vinod
Super session announcing a new @thelancet.com @iaslc.bsky.social Commission on lung cancer at this year’s WCLC 2025 in Barcelona
September 7, 2025 at 9:45 AM
Reposted by Prof Shalini Vinod
Are you thinking of studying the association of the time from cancer diagnosis to treatment and overall survival? Have a look at these consensus recommendations we developed and published in the British Journal of Cancer:

www.nature.com/articles/s41...
Recommendations for studying the association of the cancer diagnosis to treatment interval with overall survival: a modified Delphi process - British Journal of Cancer
British Journal of Cancer - Recommendations for studying the association of the cancer diagnosis to treatment interval with overall survival: a modified Delphi process
www.nature.com
September 5, 2025 at 7:37 PM
3694 people enrolled for lung cancer screening in first month of lung cancer screening in 🇦🇺 👏🏽👏🏽👏🏽 @racgp.bsky.social @togaanz.bsky.social
July 31, 2025 at 3:29 AM
A #nurse led geriatric oncology model of care is a feasible way of ⬆️ geriatric screening & assessment of older adults with #cancer. www.sciencedirect.com/science/arti...
Implementation and evaluation of a nurse-led geriatric oncology model of care for older adults with lung cancer
www.sciencedirect.com
July 17, 2025 at 10:42 AM
Lung cancer screening in 🇦🇺is finally here! Amazing amount of work from multidisciplinary group & consumers. www.health.gov.au/our-work/nlcsp Need @racgp.bsky.social support to assess patients for eligibility. It’s time to ⬆️ survival from lung cancer! @dkarikios.bsky.social @drtomjohn.bsky.social
www.health.gov.au
June 30, 2025 at 10:12 PM
Reposted by Prof Shalini Vinod
Need exercise physiologists as routine members of oncology team esp for survivorship care
June 3, 2025 at 11:04 PM
👏🏽👏🏽👏🏽 work by PhD student Dr Kim-Lin Chiew - Quality Indicators and Benchmarks for Radiotherapy in Lung Cancer: A Modified Delphi Approach - Clinical Oncology www.clinicaloncologyonline.net/article/S093... @gerryhanna.bsky.social
Quality Indicators and Benchmarks for Radiotherapy in Lung Cancer: A Modified Delphi Approach
While there are many published quality indicators (QIs) for assessing clinical care in lung cancer few specifically measure the quality of radiotherapy (RT). To address this gap, we used a structured ...
www.clinicaloncologyonline.net
May 31, 2025 at 6:29 AM
🇦🇺lung cancer screening coming 1st July. Guidelines state “ Suitability for lung cancer surgery should not be a contraindication for screening, as those with comorbidities can safely be Rx with radiotherapy (SABR) with minimal toxicities”. www.targetingcancer.com.au/dereks-story/ @racgp.bsky.social
Derek’s Story - Radiation Oncology Targeting Cancer
A game-changing radiation therapy technique called SABR is offering hope to people living with lung cancer, like Derek Peffe
www.targetingcancer.com.au
May 27, 2025 at 12:10 AM
Fascinating research on how a simple photo can be used to predict survival in cancer patients. FaceAge, a deep learning system to estimate biological age from face photographs to improve prognostication: a model development and validation study www.thelancet.com/journals/lan...
FaceAge, a deep learning system to estimate biological age from face photographs to improve prognostication: a model development and validation study
Our results suggest that a deep learning model can estimate biological age from face photographs and thereby enhance survival prediction in patients with cancer. Further research, including validation...
www.thelancet.com
May 13, 2025 at 10:37 AM
🇦🇺 guidelines for #lungcancer screening. Screening coming 1st July. Great step forward in #lungcancer Mx. Spread the word. www.health.gov.au/our-work/nlc... @newsgp.bsky.social @ausgov.bsky.social @drtomjohn.bsky.social @bensolomon1.bsky.social @dkarikios.bsky.social
www.health.gov.au
April 29, 2025 at 6:56 AM
👏🏽🎉Dr Vicky Chin on being awarded the Frank Ellis medal for greatest contribution to advancing the science of cancer
treatment in 2023 Clinical Oncology. pubmed.ncbi.nlm.nih.gov/36964031/ @unsw.bsky.social @gerryhanna.bsky.social #Cardiooncology #PhD
Validation of a Fully Automated Hybrid Deep Learning Cardiac Substructure Segmentation Tool for Contouring and Dose Evaluation in Lung Cancer Radiotherapy - PubMed
The novel hybrid automatic segmentation tool reported high accuracy and consistency over a validation set with challenging anatomical and imaging variations. This has promising applications in substru...
pubmed.ncbi.nlm.nih.gov
April 26, 2025 at 2:00 AM
Clinicians have their own specialty bias for Rx on NSCLC. Hardly surprising but how can we ensure balanced opinions for patients? Should they see all treating specialists? www.sciencedirect.com/science/arti... @iaslc.bsky.social @patientadvocacy.bsky.social
Physician Specialty Shapes Hypothetical Self-Treatment Choices for Locally 2 Advanced Non-Small Cell Lung Cancer: Is the 'Best' Option Subjective?
Recent trials show evolving paradigms in systemic therapy improve outcomes for select patients with resectable non-small-cell lung cancer (NSCLC). How…
www.sciencedirect.com
April 23, 2025 at 12:10 PM
Clinical trials of systemic Rx in NSCLC NOT assoc with time toxicity in Canada! jamanetwork.com/journals/jam...
Health Care Contact Days for NSCLC Treated in Clinical Trials vs Routine Care
This cohort study examines patterns of contact days among patients with advanced-stage non–small cell lung cancer receiving care in clinical trials compared with routine practice.
jamanetwork.com
April 23, 2025 at 12:06 PM
Surveillance with FDG PET/CT does not improve rates of curatively treated recurrences, TTR, or OS compared to ceCT in NSCLC patients after curative treatment.
www.sciencedirect.com/science/arti...
Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial
Post-treatment surveillance is recommended for non-small cell lung cancer (NSCLC) due to a high risk of recurrence, but evidence on the optimal survei…
www.sciencedirect.com
April 23, 2025 at 11:58 AM